Renal Cell Carcinoma Clinical Trial
Official title:
Operable Primary Renal Tumors: Pre and Post-operative Volume Evaluation of the Tumor and Rest of the Kidney
1. Calculation of the expected residual renal tissue volume using contrast CT in renal
tumor patients and its effect on preoperative decision making
2. Calculating the modulation between the residual normal renal tissue volume measured 6
months post operatively and the preoperative estimated normal renal tissue volume.
3. Assessment of the value of adding residual normal renal tissue volume to the PADUA score
in decision making.
4. To reach a suggested cut off value of residual renal tissue that is adequate for a NSS
trial
The oncological outcome achieved by NSS is considered equivalent to RN in patients with stage
T1 renal tumors and as the benefits of NSS become apparent, the indications and application
of NSS continue to expand to involve even higher stages of renal tumors, These trails were
successful to achieve nearly a similar oncological outcome, however the functional outcome of
the residual renal volume was not calculated because most of these studies depend only on the
radiographic stage of the tumor. And it is not logic to expose the patients to the risk of
NSS surgery with dissection of a large tumor volume to leave only small residual renal tissue
volume that may not have enough benefit. To balance this risk benefit ratio, preoperative
assessment of expected residual renal tissue volume can be calculated using contrast CT for
all patients with renal masses must be done to reach a cutoff point for the least residual
volume of renal tissue that should be left postoperatively to achieve a significant function,
and to decide whether to do NSS or to proceed to radical surgery from the start.
The technical skill of the surgeon and the anatomical features of the renal tumor are
important factors. The contribution of each factor to treatment choice and outcome are
particularly relevant because the physician treatment recommendations are subject to training
patterns biases, comfort levels and individual experience also the kidney doesn't follow an
anatomical partitioning since designation of independent renal segments based on vascular
distributions or collecting duct branching is not possible. Nevertheless, renal anatomy does
contain consistent and easily reproducible landmarks which can be used by radiologists and
surgeons to describe and quantify pertinent features of renal masses therefore Preoperative
Aspects and Dimensions Used for an Anatomical Classification (PADUA) scoring system have
emerged for quantifying the anatomical features relevant to surgical decision-making and to
predict the risk of surgical and medical perioperative complications in renal tumor patients.
1. Preoperative assessment:
1. Using contrast CT radiologist will measure the expected residual renal tissue
volume ( total renal tissue volume) and PADUA score.
2. GFR Calculation by Cockcroft-Gault formula.
2. Operative technique:
NSS will be done whenever possible by open approach, according to PADUA score hot
ischemia with clamping of the renal artery will be done in less complicated mass while
cold ischemia with cooling of the kidney surface after clamping of both renal artery and
vein will be done in more complicated masses, Enculation of the mass will be done
whenever possible, excision will be done if needed then closure of renal defect will be
done only if necessary.
Radical nephrectomy will be done only in more complicated cases that are not amenable
for NSS by open or laparoscopic approach through early ligation of the renal artery and
vein, removal of the kidney outside Gerota's fascia, with or without removal of the
ipsilateral adrenal gland, and performance of a complete regional lymphadenectomy
whenever possible.
3. Post-operative assessment:
1. In case of NSS ,immediately post operatively the volume of the mass excised will be
measured using graded jar and after 6 months contrast CT for measuring the residual
ipsilateral parenchymal renal volume and the volume of the other kidney will be
done by the same radiologist who had previously assessed the case (blinded to the
preoperative data).
2. In case of radical nephrectomy, immediately post operatively we will separate the
mass from normal renal tissue in the specimen excised then the volume of the mass
and the normal renal tissue will be measured using graded jar. After 6 months the
volume of the other kidney will be measured by the same radiologist who had
previously assessed the case (blinded to the preoperative data)
3. Residual GFR calculation by GFR Calculation by Cockcroft-Gault formula.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04987203 -
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
|
Phase 3 | |
Recruiting |
NCT06391879 -
Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Recruiting |
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A | |
Completed |
NCT02853344 -
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
|
Phase 2 | |
Terminated |
NCT04088500 -
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT05070637 -
Circulating Tumor Cell Reducing No-touch Nephrectomy
|
N/A | |
Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
Not yet recruiting |
NCT06049030 -
A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01358721 -
Phase I Biomarker Study (BMS-936558)
|
Phase 1 | |
Active, not recruiting |
NCT04503148 -
Anesthesia and Cancer Study: Renal Cell Carcinoma
|
N/A | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Not yet recruiting |
NCT05808608 -
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03323710 -
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT03052504 -
Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy
|